Skip to main content
SpringerLink
Log in

Response to Sharma et al.: Long Pulmonary Residence Time and Plasma Half-Life of Tiotropium: Implications for Pharmacokinetic Bioequivalence Studies

  • Letter to the Editor
  • Published:
Clinical Drug Investigation Aims and scope Submit manuscript

The Original Article was published on 01 June 2017

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Sharma A, Weber B, Meibohm B. Long pulmonary residence time and plasma half-life of tiotropium:implications for pharmacokinetic bioequivalence studies. Clin Drug Investig. 2017. doi:10.1007/s40261-017-0534-z.

    Google Scholar 

  2. Algorta J, Andrade L, Medina M, et al. Pharmacokinetic bioequivalence of two inhaled tiotropium bromide formulations in healthy volunteers. Clin Drug Investig. 2016;36:753–62.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Hohlfeld JM, Sharma A, van Noord JA, et al. Pharmacokinetics and pharmacodynamics of tiotropium solution and tiotropium powder in chronic obstructive pulmonary disease. J Clin Pharmacol. 2014;54(4):405–14.

    Article  CAS  PubMed  Google Scholar 

  4. Horhota ST, van Noord JA, Verkleij CB, et al. In vitro, pharmacokinetic, pharmacodynamic, and safety comparisons of single and combined administration of tiotropium and salmeterol in COPD patients using different dry powder inhalers. AAPS J. 2015;17(4):871–80.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Beeh KM, Kirsten AM, Dusser D. Pharmacodynamics and pharmacokinetics following once-daily and twice-daily dosing of tiotropium respimat in asthma using standardized sample-contamination avoidance. J Aerosol Med Pulm Drug Deliv. 2016;29(5):406–15.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Lee SL, Adams WP, Li BV, et al. In vitro considerations to support bioequivalence of locally acting drugs in dry powder inhalers for lung diseases. AAPS J. 2009;11(3):414–23.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Price D, Sharma A, Cerasoli F. Biochemical properties, pharmacokinetics and pharmacological response of tiotropium in chronic obstructive pulmonary disease patients. Expert Opin Drug Metab Toxicol. 2009;5(4):417–24.

    Article  CAS  PubMed  Google Scholar 

  8. EMA/CHMP. Questions and answers: positions on specific questions addressed to the Pharmacokinetics Working Party (PKWP). 2015. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500002963.pdf. Accessed 10 May 2017.

Download references

Author information

Authors and Affiliations

  1. Laboratorios Liconsa SA (Chemo Group), Azuqueca de Henares, Spain

    Jaime Algorta

Authors
  1. Jaime Algorta
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jaime Algorta.

Ethics declarations

Funding

No sources of funding were used to prepare this letter.

Conflict of interest

Dr. Jaime Algorta acknowledges that he is an employee of Laboratorios Liconsa S.A., as Medical Director.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Algorta, J. Response to Sharma et al.: Long Pulmonary Residence Time and Plasma Half-Life of Tiotropium: Implications for Pharmacokinetic Bioequivalence Studies. Clin Drug Investig 37, 709–710 (2017). https://doi.org/10.1007/s40261-017-0535-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40261-017-0535-y

Search

Navigation